Antihistamine use and risk of ovarian cancer

A population-based case-control study

Freija Verdoodt*, Anton Pottegård, Christian Dehlendorff, Marja Jäättelä, Jesper Hallas, Søren Friis, Susanne K. Kjaer

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

OriginalsprogEngelsk
TidsskriftMaturitas
Vol/bind120
Sider (fra-til)47-52
ISSN0378-5122
DOI
StatusUdgivet - 1. feb. 2019

Fingeraftryk

Histamine Antagonists
Ovarian Neoplasms
Case-Control Studies
Odds Ratio
Population
Confidence Intervals
Prescriptions
Population Control
Denmark
Histamine
Registries
Logistics
Logistic Models
Outcome Assessment (Health Care)
Sampling
Research

Citer dette

Verdoodt, Freija ; Pottegård, Anton ; Dehlendorff, Christian ; Jäättelä, Marja ; Hallas, Jesper ; Friis, Søren ; Kjaer, Susanne K. / Antihistamine use and risk of ovarian cancer : A population-based case-control study. I: Maturitas. 2019 ; Bind 120. s. 47-52.
@article{d4ffde528341405bb0aaeb6e4cea7fd8,
title = "Antihistamine use and risk of ovarian cancer: A population-based case-control study",
abstract = "Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95{\%} confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95{\%} CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95{\%} CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95{\%}CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95{\%} CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.",
keywords = "Antihistamines, Cancer prevention, Case-control study, Menopause, Ovarian neoplasms, Pharmacoepidemiology, Ovarian Neoplasms/epidemiology, Premenopause, Carcinoma, Ovarian Epithelial/epidemiology, Humans, Middle Aged, Risk Factors, Case-Control Studies, Adenocarcinoma, Mucinous/epidemiology, Denmark/epidemiology, Histamine Antagonists/therapeutic use, Aged, 80 and over, Postmenopause, Adult, Female, Registries, Aged",
author = "Freija Verdoodt and Anton Potteg{\aa}rd and Christian Dehlendorff and Marja J{\"a}{\"a}ttel{\"a} and Jesper Hallas and S{\o}ren Friis and Kjaer, {Susanne K.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.maturitas.2018.11.014",
language = "English",
volume = "120",
pages = "47--52",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",

}

Antihistamine use and risk of ovarian cancer : A population-based case-control study. / Verdoodt, Freija; Pottegård, Anton; Dehlendorff, Christian; Jäättelä, Marja; Hallas, Jesper; Friis, Søren; Kjaer, Susanne K.

I: Maturitas, Bind 120, 01.02.2019, s. 47-52.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Antihistamine use and risk of ovarian cancer

T2 - A population-based case-control study

AU - Verdoodt, Freija

AU - Pottegård, Anton

AU - Dehlendorff, Christian

AU - Jäättelä, Marja

AU - Hallas, Jesper

AU - Friis, Søren

AU - Kjaer, Susanne K.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

AB - Objective: Histamine is suggested to play a role in ovarian carcinogenesis. We examined the association between antihistamine use and ovarian cancer risk in a nationwide case-control study. Study design: Cases (n = 5 556) comprised all women in Denmark aged 30–84 years with a histologically verified first diagnosis of epithelial ovarian cancer during 2000-2015. Age-matched population controls (n = 83 340) were selected using risk-set sampling. Data on prescription use, patient and demographic characteristics were retrieved from nationwide registries. Main outcome measures: We used conditional logistic regression to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for epithelial ovarian cancer associated with antihistamine use (≥2 prescriptions). The association was evaluated according to patterns of antihistamine use, menopausal status, and histological subtype of ovarian cancer. Results: Ever use of antihistamines was not associated with ovarian cancer overall (OR = 0.97, 95% CI = 0.90–1.05). The lack of association remained in subanalyses for patterns of antihistamine use. We observed an inverse association between antihistamine use and ovarian cancer among pre-menopausal women (<50 year: OR = 0.72, 95% CI = 0.57-0.90), but not post-menopausal women (≥50 year: OR = 1.02, 95%CI = 0.93–1.11). In analyses of histological subtypes, an inverse association emerged for mucinous ovarian cancer (OR = 0.74, 95% CI = 0.57-0.96), but not for other subtypes. Conclusion: Antihistamine use was not associated with overall ovarian cancer risk. Additional research is needed to confirm inverse associations between antihistamine use and mucinous ovarian cancer, and overall ovarian cancer among pre-menopausal women.

KW - Antihistamines

KW - Cancer prevention

KW - Case-control study

KW - Menopause

KW - Ovarian neoplasms

KW - Pharmacoepidemiology

KW - Ovarian Neoplasms/epidemiology

KW - Premenopause

KW - Carcinoma, Ovarian Epithelial/epidemiology

KW - Humans

KW - Middle Aged

KW - Risk Factors

KW - Case-Control Studies

KW - Adenocarcinoma, Mucinous/epidemiology

KW - Denmark/epidemiology

KW - Histamine Antagonists/therapeutic use

KW - Aged, 80 and over

KW - Postmenopause

KW - Adult

KW - Female

KW - Registries

KW - Aged

U2 - 10.1016/j.maturitas.2018.11.014

DO - 10.1016/j.maturitas.2018.11.014

M3 - Journal article

VL - 120

SP - 47

EP - 52

JO - Maturitas

JF - Maturitas

SN - 0378-5122

ER -